VIH, dislipidemias y perspectivas de su evolución

Hugo  Mendieta Zerón; Angela  Montenegro Cárdenas; Joel Alberto  Vargas Hernández; Araceli Consuelo Hinojosa Juárez

doi:10.22490/24629448.3637

Vol. 17 Núm. 32 (2019)

Publicado

2019-11-15

PDF

Métricas

Cargando métricas ...

VIH, dislipidemias y perspectivas de su evolución

DOI: https://doi.org/10.22490/24629448.3637

Sección

Artículo de Revisión

Hugo Mendieta Zerón

Angela Montenegro Cárdenas

Joel Alberto Vargas Hernández

Araceli Consuelo Hinojosa Juárez

Con el advenimiento de la terapia antirretroviral (ART), la infección por el virus de inmunodeficiencia humana (VIH) se ha convertido en una enfermedad crónica con complicaciones metabólicas importantes más acentuadas que en la población general. Mientras no se tenga una vacuna que erradique las tasas de infección y no exista una cura para esta pandemia, se debe ser más incisivo en el controlar las comorbilidades, entre las que destacan las alteraciones en el perfil de lípidos pues aumentan el riesgo cardiovascular.

infección por el virus de inmunodeficiencia humana, terapia antirretroviral, perfil de lípidos, riesgo cardiovascular

Ahmed D, Roy D, Cassol E. Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy. Mediators Inflamm. 2018 Sep 27;2018:6238978.

Andrade MA, Andrade HA. Alteraciones del metabolismo lipídico en pacientes seropositivos para VIH con tratamiento Retroviral altamente efectivo. Rev. Cuban Cardiol Circ Cardiovasc. 2010;16(1):64-73.

Batterham MJ, Brown D, Workman C. Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia. AIDS. 2003;17(9):1414-1416.

Castelo Elías-Calles L, González Calero TM. Dislipidemia y virus de inmunodeficiencia adquirida/ SIDA. Rev. cuba endocrinol. 2010;21(2):202- 222.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-
1193.

Grinspoon S, Carr A. Cardiovascular risk and bodyfat abnormalities HIV-infected adults. N Engl J Med. 2005;352(1):48-62.

Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10(1):61-70.

Rodríguez-Carranza SI, Aguilar-Salinas CA. Anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin. 2004;56(2):193-208.

Husain NE, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV AIDS (Auckl). 2014;7:1-10.

Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63.

Boonthos K, Puttilerpong C, Pengsuparp T, Manosuthi W. Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. Jpn J Infect Dis. 2018;71(3):220-224.

Calza L, Colangeli V, Borderi M, Manfredi R, Marconi L, Bon I, Re MC, Viale P. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia. HIV Clin Trials. 2018;19(3):120-128.

Leyes P, Martínez E, Larrousse M, Cofán M, Trabal J, Pérez-Heras AM, Forga MT, Ros E. Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial BMC Infect Dis. 2014;14:497.

Waters DD, Hsue PY. Lipid Abnormalities in Persons Living With HIV Infection. Can J Cardiol. 2019;35(3):249-259.

García Gómez Y, Mendieta Alcántara MR, Mendieta Zerón H. Eryngium heterophyllum and Amphipterygium adstringens Tea Effect on Triglyceride Levels: A Clinical Trial. Trad Integr Med. 2019;4(1):22-27.

Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data
from INTREPID, a randomized controlled trial. EBioMedicine. 2018;35:58-66.

Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, et al. Cardiovascular risk and endothelial function in people living with HIV/ AIDS: design of the multi-site, longitudinal Endo- Africa study in the Western Cape Province of South
Africa. BMC Infect Dis. 2017;17(1):41.

D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.

Begovac J, Dragović G, Višković K1, Kušić J, Perović Mihanović M, Lukas D, et al. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Croat Med J. 2015;56(1):14-23.

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al; DAD study group. Predicting the risk of cardiovascular disease in HIVinfected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491-501.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008 Jun 28;336(7659):1475-1482.

Pierre S, Seo G, Rivera VR, Walsh KF, Victor JJ, Charles B, Julmiste G, Dumont E, Apollon A, Cadet M, Saint-Vil A, Marcelin A, Severe P, Lee MH, Kingery J, Koenig S, Fitzgerald D, Pape J, McNairy ML Prevalence of hypertension and cardiovascular risk
factors among long-term AIDS survivors: A report from the field. J Clin Hypertens (Greenwich). 2019 Aug 26. doi: 10.1111/jch.13663.

Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAILoR Study Group TAILoR (TelmisArtan and Insu- Lin Resistance in Human Immunodeficiency Virus
[HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect Dis. 2019 Jul 3. pii: ciz589. doi: 10.1093/
cid/ciz589.

Kumar S, Dhanwal DK. Central obesity & dyslipidemia in HIV patients on antiretroviral therapy. Indian J Med Res. 2018;148(4):366-368.

Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther. 2007;4:16.

Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’Curr Opin Lipidol. 2004;15(1):59-67.

Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26-39.

Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in
HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;26(9):532-40.

Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero M, del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV
Med. 2016;17(5):340-9.

Rodríguez-Díaz CE, Santiago-Rodríguez EI, Jovet- Toledo GG, Santana-Bagur J, Ron-Suarez Y, Orengo JC, Arbelaez F, Monsanto H. Comorbidities in a sample of adults with HIV in Puerto Rico: an exploratory study. HIV AIDS (Auckl).
2019;11:155-164.

Maggi P, Santoro CR, Nofri M, Ricci E, De Gennaro N, Bellacosa C, Schiaroli E, Orofino G, Menzaghi B, Di Biagio A, Squillace N, Francisci D, Vichi F, Molteni C, Bonfanti P, Gaeta GB, De Socio GV. Clusterization of co-morbidities and multi-morbidities
among persons living with HIV: a cross-sectional study. BMC Infect Dis. 2019;19(1):555.

Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, Boccara F, Capeau J. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829-840.

Brites C, Nogueira RS, Gosuen GC, Kalmar EMN, Leme ST, Martins RT, Oyama T, Bastos F. Getting older with HIV: increasing frequency of comorbidities and polypharmacy in Brazilian HIV patients. AIDS Res Hum Retroviruses. 2019 Aug 27. doi:
10.1089/AID.2019.0069. [Epub ahead of print]

Mendieta-Zerón H, Huerta-Coyote O. Dyslipidemia is a persistent problem in puerperium with or without preeclampsia. Clin Exp Obstet Gynecol. 2013;40(2):229-32.

Delicio AM, Lajos GJ, Amaral E, Lopes F, Cavichiolli F, Myioshi I, Milanez H. Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infect Dis. 2018;18(1):485.

Smith C, McFarland EJ. Update on Pediatric Human Immunodeficiency Virus Infection: Paradigms in Treatment and Prevention. Adv Pediatr. 2016;63(1):147-71.

Manafe N, Ngale A, Biquiza N, Zimba I, Majid N, Mocumbi AO. Need for active cardiovascular screening in HIV-infected children under antiretroviral therapy in Africa. Cardiovasc Diagn Ther. 2019;9(1):68-72.

Arrive E, Viard JP, Salanave B, Dollfus C, Matheron S, Reliquet V, Arezes E, Nailler L, Vigouroux C, Warszawski J; ANRS CO19 COVERTE and ENNS study groups. Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. PLoS One. 2018;13(11):e0206745

de Lima LRA, Back IC, Nunes EA, Silva DAS, Petroski EL. Aerobic fitness and physical activity are inversely associated with body fat, dyslipidemia and inflammatory mediators in children and adolescents living with HIV. J Sports Sci. 2019;37(1):50-58.

Zárate Sanabria, Andrés Gabriel et al. Intervención educativa sobre virus de inmunodeficiencia humana en la comunidad habitante de calle que asiste a un centro de acogida en la ciudad de Bogotá D.C. – Colombia. Nova, [S.l.], v. 15, n. 28, p. 11 - 17, oct. 2017. ISSN 2462-9448. Disponible en: <http://hemeroteca.unad.edu.co/index.php/nova/article/view/2072>. Fecha de acceso: 17 may. 2019 doi:https://doi.org/10.22490/24629448.2072.

Del Amo J, Campbell C, Navarro G, Segura F, Suárez I, Teira R, et al. HIV in Spain 2017: policies for a new management of chronicity beyond virological control]. Rev Esp Salud Publica. 2018 Sep 6;92. pii: e201809062.

Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, Wierzbicki AS. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017 Nov;71(11). doi:10.1111/ijcp.13032. Epub 2017 Oct 10

Ruscica M, Watts GF, Sirtori CR. PCSK9 in HIV infection: New opportunity or red herring? Atherosclerosis. 2019;284:216-217

Nawej Tshikung O, Calmy A. [Antiretroviral treatments: towards simplified regimens? Rev Med Suisse. 2018;14(588-589):102-106.

Hsu DC, O’Connell RJ. Progress in HIV vaccine development. Hum Vaccin Immunother. 2017;13(5):1018-1030.

Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner N; NHLBI AIDS Blood Session Working Group. NHLBI AIDS Blood Session Working Group. Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood. 2013;122(18):3111-3115.

Mendieta Zerón, H. ., Montenegro Cárdenas, A. ., Vargas Hernández, J. A. ., & Hinojosa Juárez, A. C. (2019). VIH, dislipidemias y perspectivas de su evolución. Nova, 17(32), 83-93. https://doi.org/10.22490/24629448.3637

Descargar cita

Publicado

VIH, dislipidemias y perspectivas de su evolución

Declaración de privacidad.

Palabras clave